Filing Date |
T Date |
Ticker |
Sector |
Ind | Industry |
Owner |
oSt |
Rel |
Title |
T |
TVal |
Price |
L |
Qty |
oc |
Own |
H |
r2y |
r1y |
r6m |
r3m |
r6w |
r3w |
r7d |
r3d |
f1d |
f1w |
f1m |
f3m |
f6m |
f1y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
3/14/23 20:39 | 3/13/23 | JNCE | Health | BioPrd | Biological Products, (No Diag | Tang Kevin C | CA | T | P.m | 86 | 0.9997 | 0 | 86 | 2 | 5,300 | I | |||||||||||||||
6/18/18 18:24 | 6/15/18 | JNCE | Health | BioPrd | Biological Products, (No Diag | Cole Hugh M | MA | O | Chief Bu | P | 15 | 7.84 | 0 | 2 | New | 2 | D | ||||||||||||||
2/2/17 17:03 | 2/1/17 | JNCE | Health | BioPrd | Biological Products, (No Diag | Karsen Perry A | MA | D | P | 80 | 16.00 | 23 | 5 | New | 5 | D | -1 | 0 | 11 | 38 | 59 | ||||||||||
2/2/17 17:03 | 2/1/17 | JNCE | Health | BioPrd | Biological Products, (No Diag | Higgons John Duncan | MA | D | P | 107 | 16.00 | 23 | 7 | 33 | 27 | D | -1 | 0 | 11 | 38 | 59 | ||||||||||
2/1/17 16:18 | 2/1/17 | JNCE | Health | BioPrd | Biological Products, (No Diag | Celgene Switzerland LLC | D0 | T | P.d | 10,000 | 16.00 | 30 | 625 | 22 | 3,456 | D | 0 | 3 | 33 | 66 |
| D | Derivative transaction in filing (usually option exercise) |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| A | Amended filing |
| E | Error detected in filing |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |